Hy-Tech Engineers Leads IPO Gainers at 47.17%
By IPO Desk
Hy-Tech Engineers leads mainboard IPOs with a 47.17% implied listing gain, offering a potential Rs 7,075 profit per lot. Other IPOs include Symbiotec Pharmalab and Skyways Air.
Hy-Tech Engineers’ IPO currently shows the highest implied listing gain at 47.17%, based on Grey Market Premium figures as of August 24.
Implied Listing Performance
- Hy-Tech Engineers, with an upper price band of Rs 53, has a GMP of Rs 25, translating to an estimated profit of Rs 7,075 per retail lot.
- Symbiotec Pharmalab, priced at an upper band of Rs 988, shows a GMP of Rs 409, offering an estimated return of Rs 6,135 per retail lot.
- Skyways Air, with an upper price band of Rs 138, reports a GMP of Rs 32, yielding an expected return of Rs 3,200 per lot.
These three mainboard initial public offerings—Symbiotec Pharmalab, Hy-Tech Engineers, and Skyways Air—opened for subscription simultaneously. They collectively aim to raise over Rs 2,475 crore from investors.
Diverse Sector Representation
The IPOs represent distinct market segments. Symbiotec Pharmalab operates in active pharmaceutical ingredients (APIs), Hy-Tech Engineers in industrial component manufacturing, and Skyways Air in global air cargo and logistics.
Key Dates for Investors
- Public issues for all three companies opened on August 24.
- Subscription is scheduled to close on August 27.
- Share allotment is expected to be finalized by August 28.
- Tentative listing on the BSE and NSE is set for September 1.
Investors are closely tracking subscription levels and broader market trends. The performance of these offerings will be a key indicator for upcoming mainboard listings.